The VEDA Group develops advanced HR software and services that help companies make their working environments fit for the future. Through continuous development, we optimize processes, increase efficiency, and focus on the needs of our customers. For more than 40 years, we have been driving digital transformation and expanding our portfolio with innovative solutions. More than 1,200 customers rely on our products every day—supported by a dedicated team that creates sustainable change with passion and an innovative spirit.

Veeva Systems builds cloud-based software for the life sciences industry, offering enterprise SaaS solutions. This posting is for upcoming 2026 computer science graduates in the Bay Area seeking entry-level software engineer roles with onsite work in Pleasanton and other locations.

At Veho, we don't sell software. We ship packages. Lots of them. We have all of the interesting problems that crop up when running twinned distributed systems in AWS and the real world.

We are building a crypto broker platform on top of centralized and decentralized exchanges.

Velo Data is a leading, profitable platform for crypto market data.

Velvet is a gateway for warehousing LLM requests, responses, and parameters. Our platform helps engineers analyze, optimize, and fine-tune their AI features.

Post-MVP AI-powered B2B SaaS; serial founder-built & self-funded (pre-angel/VC), first customers onboarding – hiring employee #2. Modernizing a software category every company needs.

Venture Global LNG is a natural gas company. Primarily, we liquify natural gas for export, but are expanding into other parts of the industry.

VerOps is building Simscope, the best hardware simulation monitoring and triage tool. This tracks millions of simulations daily, and is used by hundreds of verification engineers, across a variety of companies, to be more productive and make higher quality silicon designs.

Verge is transforming drug discovery by using artificial intelligence and proprietary human data to solve the biggest driver of rising drug costs: high clinical failure rates. They have built a large corpus of multi-modal patient molecular and clinical data sourced directly from human tissue.